|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Non-Small Cell Lung Cancer - The Need for Greater Product Differentiation in an Increasingly Crowded Market
Datamonitor, Nov 2006, Pages: 237
NSCLC comprises over 75% of all lung cancers. In 2006, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months.
Scope of this title:
- Diagnosis patterns of NSCLC including stage distribution and extent of resectability based on a survey of 180 physicians across the seven markets
- Analysis of treatment modalities and regimens according to our primary research data
- Ranking of the greatest areas of unmet need within the NSCLC market
- Physician ratings of key pipeline NSCLC candidates and the likelihood of future scenarios occurring
Highlights of this title:
According to our research, one-third of all non-resectable advanced NSCLC patients receive no drug therapy. The development of agents suitable for elderly and poor performance status patients, inducing those with existing comorbidities, provides significant commercial opportunity
While platinum-based regimens form the mainstay of first-line NSCLC treatment, our research reveals that there is little to differentiate between the available cytotoxic regimens, indicating that the efficacy of cytotoxics may have reached a plateau.
Avastin has become the first FDA approved MTT for the first-line treatment of NSCLC, labeled for administration in combination with carboplatin and paclitaxel. As more MTTs emerge from the developmental pipeline and targeted patient selection becomes more frequent, the treatment of NSCLC will undergo a transformation
Reasons to order your copy:
- Identify the key factors that influence prescribing patterns for NSCLC pharmacotherapy
- Examine the significant unmet needs in the NSCLC market and identify opportunities for new product development
- Enhance your commercial positioning through an increased understanding of NSCLC market dynamics
Customers who bought this item also bought
Non-Small Cell Lung Cancer - Avastin to Lead the Market
Drugs of Tomorrow 2001: Lung Cancer
Emerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets
Treatment Algorithms 2001: Lung Cancer
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
Pipeline Insight: Breast Cancer - A Diverse & Increasingly Crowded Pipeline
Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old Regimens
Cancer Drug Discoveries: What the Future Holds
|
|
|
|
